• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Landsdowne Labs Names Bryan Laulicht CEO

    6/13/23 9:05:00 AM ET
    $MGTX
    $AMAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Pharmaceuticals
    Health Care
    Get the next $MGTX alert in real time by email

    Company cofounder and CTO to lead button battery safety tech company toward commercialization

    The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer.

    Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M.

    Lansdowne's technology, applied to small, coin-like "button" batteries, is designed to avert injury or death when the tiny batteries--used in billions of consumer devices worldwide-- are swallowed. Studies show that every year, thousands of children and adults accidentally ingest such batteries, too often with dire results.

    Laulicht, who will assume his new position on July 3, 2023, was instrumental in developing Landsdowne's technology-- first as a post-doctoral associate in the laboratories of Robert Langer, of MIT, and of Jeffrey Karp, PhD, at Harvard, and, later, at Landsdowne.

    "Bryan Laulicht is an ideal person to lead Landsdowne toward its commercial launch," said Doug Roth, a Landsdowne Board member who is Managing Director of Investments at Connecticut Innovations (CI), a quasi-state agency that is a lead investor in the company. "Not only is Laulicht intimately familiar with the technology and the day-to-day operations of the company, but he is an experienced leader who has co-founded and built two other companies in the therapeutics, medical devices and biomaterials arenas."

    Those companies are:

    • Bullseye Therapeutics, Inc. --a Dover, Massachusetts, company providing smart injector technologies to improve the efficacy of ocular AAV Gene therapies-- acquired by Meira Gene Therapies (NASDAQ:MGTX).
    • Perosphere Pharmaceuticals, Inc. (formerly Perosphere, Inc.) -- a Danbury, Connecticut, company with a best-in-class anticoagulant reversal agent for use in life-threatening major bleeds and patients requiring urgent surgery—acquired by AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

    Laulicht holds a BA in Biophysics from Columbia University, a PhD in Medical Science from Brown University, and was a Postdoctoral Associate in the Harvard-MIT Division of Health Sciences and Technology.

    Laulicht said: "I look forward to furthering Landsdowne's mission to develop and commercialize our proprietary button battery safety technology platform. Our goal is to reduce the risk of severe injury or death when coin-sized batteries are accidentally swallowed."

    In a long-planned transition, on July 3, 2023, Laulicht will succeed Melissa Fensterstock, a Landsdowne co-founder who has served as CEO since 2017. Under Fensterstock's leadership, the company grew from academic concept to market-ready status through the formation of a global partnership with one of the world's largest metal and mining companies; patent approval; the winning of an NSF grant; and the raising of venture capital investment. Previously, Fensterstock worked across the life science sector--running corporate development for a small publicly traded biotechnology company; serving as a consumer product leader; and spinning out companies from Columbia and Johns Hopkins Universities. Fensterstock, who will remain involved with Landsdowne Labs in advisory and other Board capacities, will join a major "deep tech" venture fund that is based in Boston.

    Landsdowne Labs, LLC, formed in 2017, is a spinout from the laboratories of world-renowned Robert Langer at MIT and of Jeff Karp at Brigham and Women's Hospital, in Boston. The company's first product, ChildLok, is an innovative button battery technology designed to deactivate batteries following accidental ingestion, made possible by advanced material science. Landsdowne Labs is commercializing this groundbreaking technology for global companies seeking a turnkey, low-cost solution to the growing button battery health crisis. Landsdowne is headquartered in Fairfield, Conn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230613895741/en/

    Get the next $MGTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGTX
    $AMAG

    CompanyDatePrice TargetRatingAnalyst
    MeiraGTx Holdings plc
    $MGTX
    11/24/2025$20.00Buy
    H.C. Wainwright
    MeiraGTx Holdings plc
    $MGTX
    10/21/2025$29.00Strong Buy
    Raymond James
    MeiraGTx Holdings plc
    $MGTX
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    $AMAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on MeiraGTx with a new price target

    H.C. Wainwright initiated coverage of MeiraGTx with a rating of Buy and set a new price target of $20.00

    11/24/25 8:18:26 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on MeiraGTx with a new price target

    Raymond James initiated coverage of MeiraGTx with a rating of Strong Buy and set a new price target of $29.00

    10/21/25 7:21:05 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

    Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

    7/31/24 6:30:53 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    $AMAG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    8/14/24 6:54:38 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    $AMAG
    SEC Filings

    View All

    SEC Form 144 filed by MeiraGTx Holdings plc

    144 - MeiraGTx Holdings plc (0001735438) (Subject)

    5/19/26 9:03:54 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by MeiraGTx Holdings plc

    10-Q - MeiraGTx Holdings plc (0001735438) (Filer)

    5/14/26 8:30:23 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MeiraGTx Holdings plc (0001735438) (Filer)

    5/14/26 8:06:12 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    $AMAG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MGTX
    $AMAG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4). Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company's ordinary shares with an exercise price equal to $9.9

    5/14/26 4:30:00 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Reports First Quarter 2026 Financial and Operational Results

    Received FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)Strengthened balance sheet with $100 million financing LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2

    5/14/26 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

    LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx. The Company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to enable it to fund its

    4/16/26 7:47:22 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO & COO Giroux Richard gifted 7,000 units of Ordinary Shares, decreasing direct ownership by 0.72% to 964,530 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    5/28/26 9:04:10 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT & CEO Forbes Alexandria sold $568,540 worth of Ordinary Shares (62,000 units at $9.17) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,387,695 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    5/19/26 9:05:19 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Fleck Penny Renee

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    5/14/26 9:06:37 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    $AMAG
    Leadership Updates

    Live Leadership Updates

    View All

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Landsdowne Labs Names Bryan Laulicht CEO

    Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

    6/13/23 9:05:00 AM ET
    $MGTX
    $AMAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Pharmaceuticals

    MeiraGTx Appoints Debra Yu, MD to Board of Directors

    LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen

    4/27/22 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    $AMAG
    Financials

    Live finance-specific insights

    View All

    MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

    Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in bota-vec for the treatment of XLRP. "We are extremely pleased to have reacquired bota-vec for the treatment of XLRP,"

    4/16/26 7:10:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

    Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohortsIncreases in Unstimulated Whole Saliva Flow Rate (UWSFR) maintained out to 3 yearsAAV-hAQP1 was safe and well tolerated at each dose testedAAV-hAQP1 Data presentation webcast to be held today, April 16, 2026, at 8:00 a.m. ET LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment

    4/16/26 7:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

    - Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX) on Thursday, April 16, 2026, at 8:00 a.m. ET. The

    4/14/26 8:30:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    $AMAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    11/12/24 9:40:33 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    10/18/24 4:47:58 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

    SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

    8/14/24 7:21:27 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care